:
TO  : MTS@gnv.ifas.ufl.edu ............ Tom Sanford
    : murray@sumax.seattleu.edu ....... MaryAnne Murray
    : stever@tessi.com ................ Steve Rintala
    : SMIRNES@IMIHSRA.BITNET .......... S. Palazzi, MD
    : PHIP@TEMPLEVM.BITNET ............ Tina Phipps
    : RRICCIUT@WCU.BITNET ............. Rae Ricciuti
    : andrew@uaneuro.uah.ualberta.ca .. Andrew Penn, MD
    : IEQZ96M@TJUVM.BITNET ............ Michele Lee
    : sissi@tinman.gene.com ........... Sissi Tchehrazi
    : linda@nuhub.acs.northeastern.edu  Douglas Hanson
    : smith@alexia.lis.uiuc.edu ....... Linda Smith
    : Jim.Knox@um.cc.umich.edu ........ Jim Knox
    : Tom.Butts@um.cc.umich.edu ....... Tom Butts
    : Lori.Nelson@Forsythe.Stanford.edu Lorene Nelson
    : E1.R17@STANFORD.BITNET .......... Bob Hess
    : Norm_Oliver%NINDS31%NIH@fedtcp.ninds.nih.gov Norman Oliver
    : dlmc@med.unc.edu ................ David McIlwain
    : 
FROM: broedel@huey.met.fsu.edu ........ Bob Broedel
    :
RE  : ALS DISCUSSION GROUP 
    :


The newest treatments for nerve disorders., Ladies Home Journal, 
Dec 1992 v109 n12 p86(1).
---------------------------------------------------------------
Title:       The newest treatments for nerve disorders.
Authors:     Squires, Sally
Subjects:    Amyotrophic lateral sclerosis_Research
             Nitroglycerin_Health aspects
==============================================================================

Recent advances offer hope for devastating conditions caused by 
damage to vital nerve cells.

* Scientists are testing a drug that may be the first treatment 
for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's 
disease. People with ALS rapidly lose motor skills - about half 
die within three years. The new drug, a synthetic version of 
Human Ciliary Neurotrophic Factor (CNTF), a substance found in 
cells, has slowed the progress of ALS in animals. A study with 
several hundred people starts next month. If CNTF works, "it could 
help treat a tremendous number of neurological disorders," says 
Hiroshi Mitsumoto, M.D., director of the Neuromuscular Program 
at the Cleveland Clinic.

* Nitroglycerin, a drug often used to treat heart disease, may 
also protect nerve cells, according to a study at Boston's 
Children's Hospital. In conditions such as head trauma and stroke, 
damage is caused in part by increased levels of the brain 
chemical glutamate. Preliminary research indicates that 
nitroglycerin shields nerve cells from this chemical, says
neurologist Stuart A. Lipton, M.D., Ph.D.
==============================================================

------

Here are some international "outreach" attempts to Malasia, 
Russia, Cuba, etc. 

>
>Date   : Wed, 27 Jan 1993 10:04:54 +0800 (MYT)
>From   : Mohamed Awang-Lah <mal@jaring.ism.my>
>Subject: Re: ALS & E-mail
>To     : Bob Broedel <broedel@geomag.gly.fsu.edu>
>
>On Mon, 25 Jan 1993, Bob Broedel wrote:
>> I am trying to locate people who have an interest in 
>> communicating about ALS. This would include ALS patients, patient 
>> supporters, physicians, support groups, research centers, etc.
>
>Perhaps you can contact Prof Elizabeth Hillman (ehillman@kb.usm.my)
>---mal
>
----
>
>To     : broedel@geomag.gly.fsu.edu
>Subject: Re:  ALS & E-mail
>Date   : 27 Jan 93 11:09:29 MDT (Wed)
>From   : support2@glas.apc.org (UserSupport)
>
>Hello, this is Stass at GlasNet support2 and support. 
>Unfortunately, Kate Hunt's account on GlasNet has been 
>frozen so I cannot deliver your message to her. So I 
>forwarded it to the conference 'glas.letters'.
>Yours,   -stass  (Moscow)
>
----
>
>From   : insac@ceniai.cu 
>       : (Inst. Nac. Sist. Autom. y Tecnicas de Computacion)
>Subject: Re: ALS & E-mail
>To     : bro@huey.met.fsu.edu (Bob Broedel)
>Date   : Tue, 26 Jan 93 22:02:47 EST
>Cc     : sadmsp@ceniai.cu (Direccion SAD)
>
>> I am trying to locate people who have an interest in 
>> communicating about ALS. This would include ALS patients, patient 
>> supporters, physicians, support groups, research centers, etc.
>
>Havana, January the 26th, 1993
>
>Dear Broedel !
>I got your message as you see, I'm sendig a copy of it to the 
>Eng. Armando Rosales, Director from the Cuban Health Ministery, 
>maybe he will help you. The E. Mail of him is (Internet) 
>sadmsp%ceniai@web.apc.org, or (Usenet) web!ceniai!insac.
>
>Sincerely    Prof. Eng. RuBen Lopez Santana
>


----
From the Dow Jones stock report of 29 JAN 1993. Synergen is one
of the companies involved with CNTF clinical trials.

"Synergen gained 1 3/4 to 57 1/2, recovering from a plunge of 5 
this week following a hoax call to an industry newsletter claiming 
that a new drug being tested by Synergen doesn't work. Synergen is 
in the final phase of human tests on a drug called Antril to treat 
septic shock."

== end of als 14 ==